R&D | January 16, 2026
Redesigned brain receptor drugs show promise for depression
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
Subscribe To Our Newsletter & Stay Updated
